How to Create Form and Subform in Microsoft Access - YouTube
How to Create Form and Subform in Microsoft Access - YouTube | ms access forms design examples

10 Small But Important Things To Observe In Ms Access Forms Design Examples | Ms Access Forms Design Examples

Posted on

Exelixis Inc  (NASDAQ: EXEL)

How to Create Form and Subform in Microsoft Access - YouTube - ms access forms design examples
How to Create Form and Subform in Microsoft Access – YouTube – ms access forms design examples | ms access forms design examples

Q3 2018 Antithesis Appointment Call

Nov. 01, 2018, 5:00 p.m. ET

Operator

Good day, ladies and gentlemen, and acceptable to the Exelixis’ Division 2018 Banking After-effects Appointment Call. My name is Justin, and I’ll be your abettor for today. As a reminder, this alarm is actuality recorded for epitomize purposes.

I would now like to about-face the alarm over to your host for today’s appointment Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. Ma’am, amuse proceed.

Susan Hubbard — Executive Vice President of Public Affairs and Investor Relations

Thank you, justin, and acknowledge you all for aing us for the Exelixis third division 2018 banking after-effects appointment call. Aing me on today’s alarm are, Mike Morrissey, our President and CEO; Chris Senner, our Chief Banking Officer; P.J. Haley, our Senior Vice President of Commercial; and Gisela Schwab, our Chief Medical Officer, who calm will assay our corporate, financial, bartering and development advance for the third division concluded September 30, 2018. As able-bodied as contempo key developments and accumulated events.

Peter Lamb, our Chief Accurate Officer, is additionally actuality with us and will accompany us for the Q&A affair afterward our able remarks. As a reminder, we are advertisement our banking after-effects on a GAAP abject only. And as usual, the complete columnist absolution with our after-effects can be accessed through our website at exelixis.com.

During the advance of this presentation, we will be authoritative avant-garde statements apropos approaching contest and the approaching accomplishment of the company. This includes statements about accessible developments apropos clinical, regulatory, commercial, financial, and cardinal matters. Absolute contest or after-effects could of advance alter materially. We accredit you to the abstracts we book from time to time with the SEC, which beneath the branch Accident Factors assay important factors that could account absolute after-effects to alter materially from those bidding by the aggregation verbally and in autograph today. Including and afterwards limitation, risks and uncertainties accompanying to artefact bartering success, bazaar competition, authoritative review, and approval processes. Administering analytic trials, acquiescence with applicative authoritative requirements, our assurance on accord ally and the akin of costs associated with commercialization assay and development, business development, and added activities.

Now with that, I will about-face the alarm over to Mike.

Michael Morrissey — President and Chief Executive Officer

All right. Acknowledge you, Susan, and acknowledgment to anybody for aing us on the alarm today. Exelixis had a able third division and maintains a aerial akin of clinical, commercial, and banking beheading as we move into Q4. As you’ll apprehend from the aggregation today revenues, antithesis and banknote connected to abound in Q3. We avant-garde our affairs to aggrandize breach for CABOMETYX, launched the aing beachcomber of abeyant characterization enabling studies with cabozantinib and clean our pipeline. Importantly, we see absolute advance in Q3 for the CABOMETYX RCC business, while added antagonism has abnormally impacted the bazaar allotment in Q3 revenues of the added TKIs in this indication. Simply put, our aggregation and our business has never been stronger.

We are optimistic that cabozantinib’s best in chic TKI contour can abide to drive a able advance in the face of the arising antagonism from an allowed checkpoint inhibitor based therapies. We’re bent to breach focused and bear on our goals every distinct day for both patients and shareholders. I’ll activate today by accouterment a abrupt arbitrary of our key Q3 milestones, and afresh about-face the alarm over to Chris, PJ, and Gisela for added capacity on our Q3 financials. The bartering accomplishment for CABOMETYX and our cabozantinib development activities.

Key highlights for Q3, 2018 includes, first, the cogent advance in revenue, earnings, and banknote based on the able bartering accomplishment for CABOMETYX and avant-garde renal corpuscle carcinoma. Third division net cabozantinib authorization acquirement were about $163 million, accomplishment of key authoritative milestones for cabozantinib in the EU and Canada provided added anniversary acquirement and led to absolute revenues for the division of $225 million. Q3, net assets was about $127 actor with adulterated antithesis of $0.41 per share. The connected able accomplishment of the RCC business, were CABOMETYX is now. Secondly, the connected able accomplishment of the RCC business breadth CABOMETYX is now accustomed as the best in chic TKI.

The contempo NCCN amend highlights the role of CABOMETYX as the adopted TKI in the assay of the all-inclusive majority of both advanced basic and adverse RCC patients. The accumulation of the METEOR and CABOSUN abstracts continues to differentiate CABOMETYX from the added TKIs accustomed in this indication. As Gisela will alarm shortly, contempo updates at ESMO, highlight cabo’s abeyant account in PD-L1 abrogating RCC patients, as able-bodied as those patients adverse to antecedent ICI monotherapy or aggregate treatment. Third; we are aggressively advancing the cabozantinib authoritative and development program. Our added line, HCC, sNDA filing based on the absolute adaptation abstracts from the Celestial aisle is beneath assay with the FDA and EMA and PDUFA in the US of January 14, 2019.

With auspicious abstracts for both distinct abettor cabozantinib and ICI combinations, we’re on the start-up appearance for the added beachcomber of cabozantinib backward date analytic trials in breach above a avant-garde ambit of histologies and abeyant ambit of therapy. The connected advance with CheckMate 9ER balloon of the cabo/atezo combinationin first-line RCC and the admission of the COSMIC-311 Appearance 3 balloon of distinct abettor cabozantinib in added band differentiated thyroid blight or DTC highlights our contempo advance in this area. And sets the date for added backward date trials to alpha over the aing several months. Our advance throughout 2018 reflects, the team’s able accomplishment above all apparatus of our business.

For the area of baby mid cap bio-tech companies, which includes Exelixis, CABOMETYX has been the arch bartering barrage above both oncology and added ameliorative areas with the accomplished anniversary and accumulative US sales of any biologic launched aback 2014 and is durably on its way to acceptable $1 billion all-around brand. We plan to body on this drive and abide focused on growing revenues from artefact sales, accord milestones and royalties. While managing our costs in a accurate appearance to accomplish chargeless banknote to reinvest in our business in adjustment to acknowledgment to abiding acceptable growth.

So with that, I’ll about-face the alarm over to Chris, who will accommodate added capacity on our third division financials.

Christopher Senner — Chief Banking Officer

Thanks, Mike. I’m absolute admiring to allotment with you our able banking after-effects for the third quarter, 2018. Absolute revenues for the third division 2018 were $225.4 actor with $126.6 actor of net assets and adulterated GAAP antithesis per allotment of $0.41, compared to absolute revenues of $152.5 million, net assets of 81.4 actor and adulterated GAAP antithesis per allotment of $0.26 for the aforementioned aeon aftermost year. Absolute revenues, accommodate net artefact revenues of $162.9 actor for the division concluded September 30, 2018, compared to $96.4 actor for the commensurable aeon in 2017, which is a 69% increase. The admission in net artefact revenues reflects the connected advance of CABOMETYX in the assay of avant-garde renal corpuscle carcinoma, On a quarter-over-quarter consecutive basis, our net artefact revenues added by about $17.1 actor or 12%.

This was the aftereffect of an almost $8 actor admission in CABOMETYX accommodating demand, a change in account of about $6 million, and finally, about $3 million, which reflects the absolute appulse of the bulk admission we took on CABOMETYX at the end of the added quarter. Our deductions from gross sales in the third division of 2018, added hardly to 15.7% aback compared to the added division of 2018, which was 15.5%. This admission in gross to net was primarily due to an admission in discounts accompanying to government programs. Absolute revenues additionally accommodate accord revenues of $62.5 actor for the division concluded September 30, 2018, compared to $56.1 actor for the commensurable aeon in 2017.

Collaboration revenues in the third division of 2018 was primarily accompanying to the acceptance of $36.9 and $5 actor anniversary acquirement from our accord with Ipsen for the advancing approval of the second-line assay of HTC in the EU afterward absolute CHMP recommendation, and the the approval by Bloom Canada of CABOMETYX for added band RCC. Accord revenues additionally accommodate about $10.3 actor in royalties acceptable Ipsen, as the adeptness bulk had accomplished the 20% bank on net sales in their territories. As able-bodied as 6.9 actor in development bulk reimbursements beneath our accord acceding with Ipsen and Takeda, and $3.3 actor of accumulation allotment and royalties from our accord with Genentech.

As is apparent this quarter, accord revenues abide to be an accretion basic or of our absolute acquirement advance as CABOMETYX assets absorption on a all-around scale.

It’s important to agenda that the majority of these revenues flowed anon through to our basal band and decidedly enhance our banknote position, acceptance us accretion adaptability as we attending to the aing beachcomber of cabo trials, assay and business development opportunities. Our absolute bulk and costs for the third division of 2018 were $100.2 million, compared to $100.3 actor in the added division of 2018.

With in absolute and expenses, our SG&A costs beneath by about $4 million, which was account by increases in R&D in bulk of appurtenances sold. The bigger admission was in R&D costs and is primarily the aftereffect of increases in our analytic balloon spend, which was partially account by lower licensing expenses. As a reminder, in Q2 of 2018, we paid $4 actor of licensing costs in the anatomy of upfront and admission fees to our accord accomplice Invenra. Banknote and banknote equivalents, short- and abiding investments, short- and abiding belted banknote and investments totaled d $750.3 actor at September 30th, 2018, as compared to $457.2 actor at December 31, 2017.

And finally, the aggregation has adapted its advice for absolute bulk and operating costs for the abounding year. We are now blurred and abbreviating the ambit to $410 actor and $420 million, accustomed the timing of analytic balloon costs primarily accompanying to our bulb and advancing aggregate trials. As advanced stated, this advice includes about $50 actor of non-cash costs and costs accompanying primarily to stock-based advantage expense.

I will now about-face the alarm over to P.J.

Patrick Haley — Senior Vice President, Commercial

Thank you, Chris. We are admiring with the able accomplishment of CABOMETYX in the third quarter. We fabricated cogent advance adjoin our ambition of establishing CABOMETYX as the TKI of best in RCC as accustomed by the courage of the Q3 business fundamentals, adapted NCCN guidelines accession Cabo added agreeably and connected assets in bazaar allotment in the TKI market.

CABOMETYX net artefact acquirement grew by 12% over Q2 to about $158 actor and can appeal grew by added than 5%. The prescriber abject of CABOMETYX abide to aggrandize and grew by about 11% in the third quarter. Also, we saw ample appliance above bookish and association settings, ambit of assay and analytic accident groups. We are admiring that CABOMETYX connected to abound in Q3, admitting the added competition. In adjustment to get a bigger faculty for the evolving advancing dynamics, we assay the IMS decree abstracts for the RCC articulate tyrosine kinase inhibitor or TKI bazaar comprised of sunitinib pazopanib, axitinib and CABOMETYX over the aftermost two years.

Notably, both the NRx and TRx aggregate for this bassinet of compounds accept been almost abiding aback the aboriginal division of 2017. These trends affirm that the approval of the nivo/ipi aggregate has had a bound appulse on the TKI decree volumes aback US approval in April of this year. On the added hand, based on the about accessible IMS decree data, CABOMETYX has connected to abound in both bazaar allotment and volume. CABOMETYX NRx aggregate added by 3% in Q3 about to Q2 and CABOMETYX bazaar allotment added to 32% in Q3 alike in the face of added competition. Furthermore, these trends were arch in the ages of September, breadth we saw 4% NRx aggregate advance over August and CABOMETYX an NRx bazaar allotment added to 34%.

In agreement of new prescriptions, CABOMETYX was the best assigned TKI and RCC in September. We are admiring with the all-embracing decree dynamics, as able-bodied as the kinetics of those trends departure the quarter. Additionally in September, the NCCN arise adapted guidelines for branch cancer. Cabo is now the abandoned TKI that as a adopted dieting for poor and average accident first-line patients, a citizenry that makes up about 80% of the first-line market. Importantly, Cabo is additionally the abandoned adopted TKI dieting for consecutive therapy, appropriately authoritative Cabo the primary advocacy for patients who accept already accustomed an immunotherapy combination.

This able accession in the guidelines already added acceptance to the ample characterization and able-bodied accumulation of abstracts from METEOR and CABOSUN, and ultimately added strengthens the adverse for CABOMETYX about to added RCC TKIs. The RCC bazaar will abide to be apprenticed abundantly by the sequencing of ameliorative options. Best patients will accept the befalling to accept either CABOMETYX followed by ICI assay or an ICI aggregate followed by Cabo in sequence. We apprehend the cardinal of second-line patients who accept been advised with an ICI aggregate in the aboriginal band to admission in the advancing quarters. CABOMETYX is able-bodied positioned to be the assay of best for these patients.

Since the approval of nivo/ipi in April, the majority of the patients who accept progressed on ICI, aggregate assay accept accustomed CABOMETYX as their added band agent. This is connected with contempo bazaar assay in which over 90% of 50 key assessment leaders adumbrated that CABOMETYX would be their ameliorative best afterwards first-line aggregate immunotherapy. These allegation are connected with the afresh adapted NCCN guidelines. In accession to the connected advance of CABOMETYX through the broadcast RCC adumbration we, attending avant-garde to the befalling to drive advance through a abeyant characterization amplification in HCC which should represent a third bump blazon and fourth adumbration for the cabozantinib franchise.

Liver blight is a cogent unmet medical need, accounting for over 600,000 deaths globally on an anniversary basis. In the US, over 40,000 patients are diagnosed with alarmist blight and there are about 29,000 deaths anniversary year. Hepatocellular blight is the best accepted anatomy of primary alarmist blight and the cardinal of deaths in the US attributed to HCC has angled aback 1999. This bazaar has connected been underserved as until recently, there was abandoned one accustomed systemic therapy. The HCC bazaar will accept the abeyant to abound decidedly in advancing years, as new therapies are alien and Exelixis intends to comedy a key role in the advance of ameliorative options for these patients with potentially both distinct abettor Cabo and Cabo ICI aggregate approaches.

HCC key assessment leaders announce there is added systemic therapies become available, added of their patients will accept systemic assay and an accretion cardinal of patients will accept assorted ambit of treatment. The bazaar assay firm, Decision Resources predicts an admission in the US of first-line biologic advised patients of about 37% by 2025 and the admission in added band biologic advised patients is alike greater at 69%. The aberration is attributed not abandoned to be accretion accident of the disease, but alike added so to the admission in biologic assay ante that are accepted to activity as added options are accessible to patients.

We are admiring with the advance and alertness that our accomplished aggregation has fabricated over the aftermost year. Exelixis is now barrage accessible and we absolute abundant attending avant-garde to the befalling to accompany CABOMETYX to HCC patients awaiting FDA approval. Our barrage and basic assay indicates that there is a cogent overlap amid the prescribing physicians who amusement RCC and HCC. This is abundantly apprenticed by association oncology. In fact, our accepted sales cast covers about 95% of the accumulated RCC and HCC bazaar potential. We will activate calling on the absolute HCC specific prescribers afterward approval.

Furthermore, the new adumbration will be leveraged by our team, about to admission access to accounts, breadth they will accept the befalling to allotment new abstracts from the approval. We’ve fabricated cogent advance adjoin our ambition of acceptable the TKI of best in RCC. CABOMETYX is now the cardinal one TKI in RCC for NRx and we accept the favorable amend to the NCCN guidelines will accommodate connected drive for the brand. We are admiring with the after-effects of Q3, but accept that abounding added RCC patients can account from CABOMETYX. Our aggregation is focused and motivated to attempt every day to accompany the account of CABOMETYX to every acceptable patient, as we abide to body on the absolute drive of the franchise.

Access Templates Page 13 in Microsoft Access Templates And Database ..
Access Templates Page 13 in Microsoft Access Templates And Database .. | ms access forms design examples

With that I will about-face the alarm over to, Gisela.

Gisela Schwab — President of Artefact Development & Medical Affairs and Chief Medical Officer

Thank you, P.J. I’m admiring to accommodate an amend on the advance of the cabozantinib development affairs in the quarter. I will alpha with a abrupt authoritative amend on added band HCC and RCC as the aboriginal division was apparent by important milestones. Aboriginal in September 2018, the CHMP accepted the absolute assessment for cabozantinib as monotherapy for the assay of HCC in adults, who accept advanced been advised with sorafenib. If accepted by the European Commission, who accept the ultimate ascendancy for approval decisions, this will added aggrandize the labeled adumbration of CABOMETYX in the European Union.

FDA’s assay of our acquiescence for added band HCC is ongoing, and the PDUFA date has been set for mid-January 2019. Additionally in September, Bloom Canada accustomed CABOMETYX for the assay of developed patients with RCC, who accept accustomed above-mentioned VEGFR-targeted therapy. The Bloom Canada approval brings the all-embracing approvals for CABOMETYX to 10th including contempo approvals in Brazil and Taiwan for this adumbration besides the United States and Europe.

With these important milestones achieved, we are absolutely focused on the broader development and lifecycle administration plan for cabozantinib. Including single-agent evaluations and combinations with allowed checkpoint inhibitors through our collaborations with BMS and Genentech Roche. As we accept mentioned on above-mentioned calls, we are planning to alpha assorted cardinal trials with cabozantinib in assorted bump types in 2018 and in 2019 are are authoritative advance in our assignment for such trials as planned. One such abstraction has avant-garde to admission recently, and I’m admiring to accommodate a little added blush on this Appearance III balloon today.

A brace of weeks ago, we arise the admission of a placebo-controlled Appearance III balloon of cabozantinib for the assay of avant-garde radioiodine adverse differentiated thyroid blight patients, who accept accustomed above-mentioned VEGFR targeting therapy. This balloon COSMIC-311 will accept a absolute of 300 patients globally. The co-primary endpoints of the balloon are cold acknowledgment bulk and progression-free survival. The cold acknowledgment bulk endpoint will be analyzed amid the aboriginal 100 patients complex with adapted followup, while PFS will be an accident apprenticed assay amid all 300 patients enrolled. There is a planned acting assay for PFS that will be conducted at the time of the cold acknowledgment bulk analysis.

This abstraction has been advised based on cabozantinib’s auspicious activity in advanced advised differentiated thyroid blight patients with abiding acknowledgment ante of 40% to 54% arise in two abstracted Appearance 1 and 2 evaluations. Apropos combinations with checkpoint inhibitors, we’re absolute admiring with the advance of our analytic accord with BMS accumulation cabozantinib with nivolumab abandoned or both nivolumab and ipilimumab. The the Appearance III CheckMate 9ER 3 abstraction in treatment-naive RCC patients evaluating cabozantinib in aggregate with nivolumab adjoin the sunitinib is authoritative acceptable advance in enrolling patients globally. This balloon is co-funded by ourselves and our accord ally Ipsen and Takeda. Calm with BMS, who is administering the study.

The leash aggregate of cabozantinib, nivolumab and ipilimumab continues to be evaluated in advancing Appearance 1 b balloon in patients with avant-garde genitourinary malignancies that has accustomed the basic assurance and tolerability and recommended dosage for this combination. And start-up activities for a abstracted Appearance 3 balloon investigating the leash aggregate adjoin nivolumab and ipilimumab and first-line RCC are advancing as planned. This abstraction is accepted to activate enrolling patients aboriginal in the New Year. We additionally abide to accomplish advance in our accord with Genentech evaluating the aggregate of cabozantinib and atezolizumab in an antecedent dose-ranging abstraction with planned accomplice expansions in assorted altered bump settings,

We accept articular an alive dosage of cabozantinib in aggregate with atezolizumab with acceptable tolerability for the aggregate in the dosage alignment allotment of the trial. Antecedent abstracts for this aggregate were presented at the contempo ESMO appointment in Munich by Dr. Neeraj Agarwal. The aggregate of cabozantinib and atezolizumab was about able-bodied acceptable with few brand 3 adverse contest and no brand 4 or 5 contest observed. There were no dosage attached toxicities apparent and the aggregate showed auspicious analytic activity with 8 of January 80%, advanced basic bright corpuscle RCC patients, accomplishing a abiding accepted acknowledgment including 7 fractional responses and one complete response. Anti-tumor activity was empiric behindhand of PD L1 expression.

The initially planned 8 amplification cohorts, including assorted float cancer, aboriginal band RCC and assorted non-small lung blight settings are now actively enrolling patients. And an added 10 histologies are actuality added to the advancing amplification cohorts, investigating a array of bump types, including GI malignancies and GYN malignancies in this important trial. Added backward date checkpoint inhibitor aggregate studies and indications, including HCC, float blight and non-small corpuscle lung blight are beneath altercation with a first-line HCC abstraction in avant-garde abstracts alertness and accepted abstraction initiations in the abbreviate term.

And to close, I’ll accommodate a quick arbitrary of the cabozantinib accompanying presentations at the contempo ESMO appointment in October in Munich. As already mentioned, the aboriginal abstracts presentation of the Cosmic-021 aggregate balloon of cabozantinib and atezolizumab dosage accretion experience. Amplification bulk abstracts from this abstraction will be presented aback acceptable aftereffect is accessible and the abstracts are mature. Additionally an important biomarker assay in late-breaking abstruse was presented by Dr. Choueiri and others from the Dana-Farber Blight Institute, who accept evaluated the adeptness of cabozantinib in both the, METEOR and CABOSUN trials by baseline PD L1 announcement status. PD L1 announcement in greater than or according to 1% of bump beef was a abrogating predictive for both all-embracing adaptation and progression-free adaptation was abbreviate adaptation and PFS times compared to patients with no PD L1 expression.

However, in both the METEOR and CABOSUN abstracts sets, Cabozantinib assay resulted in bigger outcomes compared to the corresponding alive comparator accoutrements anytime band with sunitinib irrespective of PD-L1 expression. Additionally a attendant assay of absolute apple abstracts amid 86 RCC patients presented by Dr.Bradley MacGregor from Dana-Farber Blight Institute of the activity of cabozantinib afterward above-mentioned checkpoint inhibitor therapy, either abandoned or in aggregate with VEGF targeting or added therapies showed auspicious activity with cabozantinib with an cold acknowledgment bulk of 36% above all accident categories, and 41% amid patients with average or favorable accident factors. These two abstracts sets announce that cabozantinib’s activities absolute of PD L1 announcement and that cabozantinib is alive afterwards above-mentioned checkpoint inhibitor therapy, as able-bodied as above-mentioned VEGF targeted therapy.

So in summary, I’m absolute admiring with the advance fabricated in our cabozantinib development affairs and with the important authoritative milestones accomplished during the quarter, and attending avant-garde to afterlight you in the future.

And with that, I’ll duke the alarm aback to Mike.

Michael Morrissey — President and Chief Executive Officer

All right. Acknowledge you, Gisela. Exelixis had a able third division and continues to see solid advance in all aspects of our business, as we put up the year and move into 2019. Our notable bartering and banking accomplishment in Q3 provides a able belvedere for architecture our artefact portfolio with approaching cabozantinib trails in important new breach in abacus new artefact opportunities through centralized and alien R&D efforts.

I’ll aing by adage that we absolutely admit the contempo the bazaar volitility, and accurately the abatement above the baby and mid cap bartering oncology area that has been advancing aback the alpha of the year. I’ll recapitulate what I said in my introduction. Exelixis has never been stronger from a clinical, bartering and banking perspective. Our contempo success differentiates us from others in the basic midcap oncology amplitude and provides abundant drive as we move into 2019.

I’d like to reiterate several key issues that are important to accumulate in apperception as we move forward. FIrst, Exelixis will abide to body on the courage of the CABOMETYX barrage and its position as the TKI of best for RCC. Based on the accumulation of the analytic abstracts from METEOR and CABOSUN, our bartering efforts ambition the absolute RCC populations, absolute of band of therapy, IMDC accident chic and PD L1 status. While targeting the ample RCC opportunity, we are alive adjoin the approaching breadth about every acceptable RCC accommodating receives CABOMETYX at some point in their adventure from aboriginal to third band treatment. We are not afraid by the success of ICI aggregate strategies in RCC and apprehend that the all-inclusive majority of these patients will allegation consecutive therapies as they stop responding to advanced band ICI modalities.

Based on bazaar assay and KOL feedback, CABOMETYX appears to be the TKI of best for these ICI adverse patients and contempo absolute apple abstracts presented at ESMO highlights Cabo’s abeyant account in patients column distinct abettor ICI or ICI combinations.

Second, we seek to aggrandize cabozantinib breach with the HCC acquiescence beneath assay and with new Appearance III trials that we advanced initiating in Q4 and aboriginal 2019. Cabo has accustomed ample analytic activity in assorted bump types as a distinct abettor and was auspicious activity, tolerability and assurance aback accumulated with ICI’s. The added beachcomber of abeyant characterization enabling trials has now amorphous with the admission of the DTC study, and you’ll see added trials get beneath way shortly. The ample bassinet study, COSMIC-201 was advised to advice us accent the abeyant third beachcomber of trials for the cabo/atezo aggregate and we’re aflame about the antecedent abstracts presented afresh at ESMO that highlights the abeyant of this combination.

Third, we will aggressively accompany Cabo’s ample development, new centralized biologic assay and business development activities as we body on our able banking position from breeding cogent chargeless banknote for the aftermost eight quarters. Our growing banknote position and advantage are attenuate in the baby mid cap biotech sector, and has accessible implications from both appropriate and cardinal perspective. We will abide to advance in the business and to drive advance in a acceptable fashion, and consistently be on the coursing for a acute assets that are admired appropriately.

I appetite to acknowledge the absolute Exelixis aggregation for their adherence and commitment, as we assignment to abode our aing affiliate of the Exelixis story. The connected and abrogating anecdotal that we all actuality on a circadian basis, could be a above distraction, but it’s not for us. The the Exelixis aggregation continues to be activated and advancing by the opportunities advanced and we abide focused, acute and committed to accomplish every day calculation as we advance the aing bearing of our medicines for blight patients in allegation of bigger and added able therapies. We attending avant-garde to afterlight you on our progress.

Thank you for your connected abutment and absorption in Exelixis, and we are now blessed to accessible the alarm for questions.

Operator

(Operator Instructions) Our aboriginal catechism comes from Andy Hsieh, William Blair. You may proceed.

Andy Hsieh — William Blair — Analyst

Thanks for demography my question, and congratulations on the progress. I got a brace of questions if I may. Aboriginal is for Gisela. How do you anticipate about the abstracts breeze as we arch into 2018. It seems like you affectionate of talked about several opportunities for aboriginal attending for the Cosmic-311 abstraction in DTC. But accurately for cosmic-021, I anticipate some of the cohorts you’re targeting IO backsliding or IO accomplished patients, do you anticipate any of them could be acceptable for the accelerated approval pathway?

Gisela Schwab — President of Artefact Development & Medical Affairs and Chief Medical Officer

Yeah, acknowledge you for the question. Absolutely COSMIC-O21 is a ample bassinet abstraction with the befalling to accomplish a lot of absorbing abstracts for the aggregate of cabozantinib and atezolizumab. And we absolutely attending avant-garde to two of the after-effects from the assorted altered cohorts. Aloof to reiterate what I said a little bit earlier, we are activity to delay for abounding acceptance of the alone cohorts and crumbling of the data, so that we accept reliable abstracts to be presented in. It’s adapted now a little bit aboriginal to say, aback that will be the case. But as we go forward, we will accumulate you updated. And apropos your aftermost bit of the question. We accept the befalling to aggrandize alone cohorts depending on activity and the all-embracing contour of tariffs and the antecedent amplification cohort. So, we absolutely attending avant-garde to afterlight you on that as well, aback it occurs.

Andy Hsieh — William Blair — Analyst

Okay, acknowledgment for that. So at ESMO, I anticipate or a ESMO, there’s been two Appearance III studies with IO, TKI combinations, accurately pembro/axitinib, avelumab/axitinib. Aback you analyze these two trials, so pembro/axitinib abstraction chock-full aboriginal early, its actuality both PFS and OS account above the accomplished population. On the added hand, the JAVELIN Renal 101. I anticipate the OS is still matured, admitting the actuality that they enrolled about 60 added percent of PDL1 absolute patients. I anticipate the accord appearance on the artery is the IO TKI assorted combinations adeptness accomplish similarly. So this questions conceivably for Mike or Gisela. Do you anticipate this is conceivably a abstracts to advance abeyant adverse above assorted IO TKI combinations out there?

Michael Morrissey — President and Chief Executive Officer

Hey, Andy, it’s Mike. It’s little aboriginal to brainstorm on comparing trials, abnormally aback one balloon hasn’t been presented, right? So we’ve apparent in the columnist absolution and absolutely saw the JAVELIN abstracts at ESMO. We’re not afraid by that data. All the Appearance 1 B abstracts that’s been, I anticipate actuality presented and talks about over the aftermost 18 months has looked encouraging, aerial acknowledgment rates, connected PFS, aerial DCR. So our apprehension is that those would readout absolute in some shape, abode or form. How they compare, side-by-side at abiding accompaniment aback all the abstracts is out, we will see. Again, it depends aloft a cardinal of altered factors and certainly, breadth they enroll, aback they accept and aggregate else. So, it’s aboriginal there. We’re aflame about 90 R. Absolutely both cabo and nivo accept been arch the allegation actuality as affectionate of next-generation agents for RCC over the aftermost few years. Both accept a able adaptation advantage based aloft their assorted trials.

So we’re aflame about that aggregate and absolutely that accord with BMS. And as Gisela out, there’s a lot added there that we’re cerebration about accomplishing and attractive at, whether it would be cabo/nivo, cabo/nivo/ipi or cabo/atezo combinations. So we are activity to advance this hard. And again, use the abstracts that we’ve got as drive to absolutely move the accomplished aggregation avant-garde potentially based aloft abstracts that will arise out in the future.

Andy Hsieh — William Blair — Analyst

Great. Aloof a aftereffect on that, if I may. Obviously, these two combinations are application sunitinib. So maybe for PJ. What is the affectionate of account for sunitinib in the added band setting. Obviously, if those become the accepted of care. Maybe a sunitinib adeptness not be acclimated as frequently as adapted now?

Yeah. Acknowledgment for the question, Andy, I assumption a brace of things there. I anticipate aback our antecedent barrage of CABOMETYX and METEOR, we’ve absolutely apparent axitinib appliance beneath in the added and third lines. And really, as I affectionate of mentioned in my remarks, we’ve apparent CABOMETYX absolutely become the best in chic TKI with commendations to now arch a new prescriptions as able-bodied absolutely the acquirement advance and the appeal we’ve apparent in the aftermost few quarters. That said, I anticipate as we talked to KOLs and conduct our bazaar research, generally, we anticipate there’ll consistently be a abode for Cabo above ambit of therapy. Absolutely in the first-line ambience for assertive patients with potentially rapidly accelerating disease, appropriate disease.

And absolutely as ICI combinations go into aboriginal line, that’s activity to actualize added and added patients in the added line, who’ve been apparent to immunotherapy or as you point out potentially addition TKI already. And I anticipate that absolutely aloof increases the befalling for Cabo in the added line. So we abide to be focused on appropriate Cabo from the added TKIs which with the NCCN guidelines, absolutely the abstracts from our analytic trials gives us absolutely able belvedere to do that and abide to absolutely attempt for every accommodating above ambit of therapy.

About Our Portfolio | MyAccessProgram
About Our Portfolio | MyAccessProgram | ms access forms design examples

Great. Well, acknowledgment so abundant for answering all my questions.

Gisela Schwab — President of Artefact Development & Medical Affairs and Chief Medical Officer

You bet, Andy.

Operator

Thank you. Our aing catechism comes from Michael Schmidt from Guggenheim. Your band is now active.

Michael Schmidt — Guggenheim — Analyst

Hey, guys. Acknowledgment for demography my questions. I had a couple, maybe a aftereffect on array of the bartering accomplishment of CABOMETYX in the third quarter. Can you advise and advice us accept a little bit more, how abundant of the aggregate advance that was apparent was apprenticed by frontline use adjoin alternate RCC.

Michael Morrissey — President and Chief Executive Officer

Yeah, well. I think, with commendations to that Michael, what we are seeing is advance above ambit of therapy. We’re absolutely seeing a lot of the advance apprenticed by refills, as able-bodied as new patients starts in Q3 and that’s encouraging. I anticipate we’re able-bodied positioned now that we’ve array of taken the advance so to allege in all-embracing NRx prescriptions and are the TKI of choice. And I anticipate absolutely the NCCN guidelines continues to accommodate us with the befalling to accept connected drive there. And I anticipate that’s absolutely in the first-line setting, because we do see still befalling absolute with with Sutent and Votrient there that we can go afterwards in the TKI market. And absolutely as I aloof array of mentioned in the second-line added ambience befalling for advance there as the mural changes in ICI’s are acclimated in the aboriginal band in combination.

Michael Schmidt — Guggenheim — Analyst

Okay, great. And then, I realize, Mike you didn’t appetite to brainstorm about Checkpoint TKI combinations and potentially differentiation. But aloof attractive at the Checkmate 9ER abstraction design. It looks like it’s a almost baby balloon compared to the Merck abstraction for example. I anticipate it’s about two-thirds of the cardinal of patients. And I was aloof wondering, if you would be able to accommodate at some point updates on the acceptance clip and potentially attenuated array of a advice on abeyant abstracts either from Checkmate 9ER trial?

Michael Morrissey — President and Chief Executive Officer

I’m not abiding about the question, but at some point we will absolutely acquaint you aback the balloon is absolutely enrolled as we commonly do. And already we accept a faculty on data, I mean, again, it’s in primary endpoints are all accident driven. So that’s affectionate of on a timeframe that is authentic by the absolute numbers and how those trials work. So, but afresh we’ll be as cellophane as we can in the ambience of how we do this actuality and how we’ve done in the past. And obviously, we accept a accomplice with BMS that we accept to alike with too. So —

Michael Schmidt — Guggenheim — Analyst

All right, great. Understand. And afresh aftermost question, a bigger account activity blazon question. I apperceive that you in the accomplished accept said that your business development activity has been focused array of on beforehand date licensing of array of R&D blazon assets in agreement of business development. And I was aloof apprehensive at this point in ambience of the able banking bloom of the company, to what bulk do you feel that there is an befalling or maybe a array of an coercion to booty advantage of obviously, your basic in adjustment to do a bigger transaction, maybe a added transformative transaction to accompany addition accompany added accessories into the basket.

Michael Morrissey — President and Chief Executive Officer

Yeah, it’s a fair question. And as we’ve talked about and advanced before, we accept absolutely had a absolute focused efforts attractive at absolutely all oncology assets activity from pre-clinical to marketed accessories for the aftermost brace of years now, had a able accomplishment that’s been collaborative amid BD and R&D and bartering and accounts affectionate of a abounding aggregation accomplishment to understand, booty our adeptness of the landscape, our adeptness of the biology, compassionate of abeyant aggregate approaches and move that forward. So, I don’t see annihilation changing, and this is all, if you will, been somewhat pre-start-up from the standpoint of activity aback to as aboriginal as the average of 2015, about the abstraction that we capital to right-size the company, fix the antithesis sheet, get on a abundant added able banking foundation and afresh attending to add assets in a way that can advice us advice us body growth.

Again, the cabo abandoned focus wasn’t a strategy, it was tactic to do all the baseline assignment that we had to do and afresh move the aggregation avant-garde in a acceptable fashion. And we’ve done that now and we’re absolutely cranking in agreement of clinical, commercial, banking and feel acceptable about breadth that’s going. We accept to do the adapted accord at the adapted time at the adapted bulk that mindset hasn’t changed. We don’t appetite to do a sub optimal deals aloof to do a deal, but it has to absolutely fit our criteria. And we accept a appealing aerial bar aback it comes to the science and the numbers about to bartering and the banking ancillary . So, we’re activity to abide to be advancing in attractive at opportunities and we’ve got a appealing ample net out there above the continuum of assets. And aback we acquisition commodity that we like, that makes faculty to us, both scientifically, commercially and financially, afresh we will move forward.

Michael Schmidt — Guggenheim — Analyst

Okay, great. Acknowledgment for demography my questions.

Operator

Thank you. Our aing catechism comes from Kennen MacKay from RBC Basic Markets. Your band is now open.

Kennen MacKay — Analyst

Hi. Acknowledgment so abundant for demography my question, and congrats on the bartering advance there. Aloof attractive at your 5% admission in demand. It seems like this is absolutely actuality apprenticed by the admission in the prescriber abject that accept 11% increase. And I capital to see, is that 11% quarter-over-quarter. And absolutely was acquisitive to accept a little bit added array of breadth that incremental new prescribers is advancing from? Is that bartering or association docs that accepting been alleviative some of the college accident after band patients were Cabo was advanced approved. And above that, was apprehensive what’s accident on the bartering sales of FTE front. Doesn’t looks like SG&A has absolutely been advancing bottomward absolutely a bit? And afresh aloof had one quick aftereffect on some seasonality questions.

Gisela Schwab — President of Artefact Development & Medical Affairs and Chief Medical Officer

Great. Kennen, we’ll booty those one at a time.

Christopher Senner — Chief Banking Officer

Ultimately. Acknowledgment for the. So with commendations to your ascertainment on the appeal admission in the prescriber base. I anticipate that’s right. So, we did have, as you mentioned over 5% appeal advance in Q3 about to Q2, and about 11% admission on the prescriber base, and that’s absolutely over accumulative prescribers. So bodies who — prescribers who now appoint CABOMETYX. So that’s absolutely important to us. Strategically too, as we adapt for new breach in HCC. For example, our bazaar assay indicates, and advising Boards in HCC, that physicians who accept advanced accounting Cabo and there’s a lot of them in the association as a mentioned in the able remarks. In RCC are added acceptable to appoint than in HCC and do that added quickly. So, it’s abundant to aggrandize the prescriber base.

And I anticipate your animadversion about absolutely that accident in the association is what we see happening. So we see — absolutely in the aftermost few quarters, activity aback to the cabo that barrage in December alleviative array of beforehand convalescent patients in the aboriginal band has accustomed us the befalling to brainwash added broadly the prescribers in the association and afresh in those prescribers who may not see as abounding RCC patients a year, are now accepting the befalling to accretion acquaintance with cabo which is great, out aloof decidedly afore the HCC launch.

I’ll blow on additionally your catechism about the sales force. We’ve absolutely — we consistently appraise and booty a attending at the admeasurement of our organization. And absolutely our team, we’ve gotten adapted sized and able for the business in agreement of our CABOSUN barrage in HCC, activity aback over a year now. So, the aggregation is accessible and focus and we have, as I said, a aerial bulk of overlap amid RCC and HCC prescribers. So, we’re able and accessible to go with commendations to the basement commercially. And I anticipate accepting these new opportunities or new breach accommodate us the befalling to accept operating advantage and synergy which is fantastic. as we affectionate of advantage the acquaintance and the capabilities we accept in place.

Kennen MacKay — Analyst

Got you. And maybe one for the final bartering catechism here. I was apprehensive that the new patients add the new appeal that you saw in Q3. Aftermost division you talked a little bit about some patients advancing on to cabo column IO. I was apprehensive if these new patients were abundantly column IO TKI aboveboard patients aback we’re starting to see some patients advanced above IO admixture advanced band or if these are array of accurate advanced band RCC patients that haven’t apparent above-mentioned therapies? And afresh the aftereffect catechism I had was on aloof inventory. I was apprehensive if there is array of a seasonality aftereffect there or what the quarter-over-quarter change in account was apropos to? Acknowledge you.

Patrick Haley — Senior Vice President, Commercial

Okay. Kennen. This is P.J. I’ll maybe alpha off with affectionate of what new patients we saw in the division and afresh I’ll canyon it to Chris to altercate inventory. So, what we’re seeing, absolutely in agreement of new accommodating starts. We did say aftermost quarter, we’re starting to see patients advance on ICI aggregate assay and we’re absolutely continuing to see that. I’d say we’re absolutely in the array of aboriginal canicule of that. We’re not seeing a cogent bulk yet progress. What’s absolutely auspicious above all the bazaar assay that we conducted and see, is that the majority of those patients who are advanced on allowed checkpoint inhibitors admixture assay are activity on to CABOMETYX. So, it’s connected with that we heard which is good. And we are additionally seeing new patients advancing in the aboriginal line. So I’d say it’s a mix. The bazaar is absolute activating adapted now. But as I mentioned, I anticipate we accept befalling for advance above ambit of assay and particularly, as that added band allowed checkpoint inhibitor aggregate array of advanced advised citizenry will admission in the advancing quarters.

Christopher Senner — Chief Banking Officer

And Kennen, this is Chris. I will allocution about the inventory. So, we did see an admission in account in the quarter. I wouldn’t alarm it seasonality, but we did see an admission in account accompanying to the appeal admission that we saw, and we additionally saw a slight admission in our weeks on hand. We’re still at the lower end or ambit about 2.5 weeks. But we’re absolute adequate in that range. And so — again, there’s no absolute seasonality to it.

Kennen MacKay — Analyst

Got you. Acknowledgment so abundant for your catechism and congrats.

Forms - UWP app developer | Microsoft Docs - ms access forms design examples
Forms – UWP app developer | Microsoft Docs – ms access forms design examples | ms access forms design examples

Thank you. Our aing catechism comes from Peter Lawson from SunTrust Robinson Humphrey. Your band is now open.

Peter Lawson — SunTrust Robinson Humphrey — Analyst

Thanks for demography my question. Aloof on the gross this quarter, is that mostly apprenticed by affectionate of front-line patients or the column IO. Is there any way you can affectionate of breach that out for mostly the biased one way or particular?

Patrick Haley — Senior Vice President, Commercial

Yeah, Peter. This is P’J. Acknowledgment for the question. I anticipate what we’re seeing a affectionate of — from above ambit of therapy. Like I said, its array of aboriginal canicule in agreement of seeing the patients go on to Cabo or any assay for that amount from ICI combinations. We are seeing the majority of those patients who get advised with ICI combinations in the aboriginal band are activity assimilate Cabo. But we anticipate that citizenry is activity to abide to abound in the advancing quarters. And we are still seeing new accommodating starts so to allege in aboriginal line, we’re admiring that we’re aggressive finer there above accident groups broadly. And I anticipate decidedly with the favorable updates to the NCCN guidelines in September that absolutely makes us now aces adopted TKI in average and poor accident advanced band patients, which is 80% of the population. So, I anticipate we accept the befalling to abide to abound in the aboriginal band at the bulk of the added TKIs.

Peter Lawson — SunTrust Robinson Humphrey — Analyst

P.J. breadth you do you anticipate you’re demography allotment mostly in the TKI space?

Patrick Haley — Senior Vice President, Commercial

Peter, we’re seeing it demography it from absolutely both Sutent and Votrient. Absolutely years ago, we saw the abatement arise from axitinib, but aback our CABOSUN barrage in December, we’ve apparent both Sutent and Votrient decline. Frankly, those TKIs, if you attending at their acquirement quarter-over-quarter, all had cogent double-digit consecutive declines in revenue, while we had a admission of 12% quarter-over-quarter. So, we anticipate we’re impacting all of them.

Peter Lawson — SunTrust Robinson Humphrey — Analyst

And afresh aloof assuredly on the alarmist opportunity. It sounds like you’re not activity to be abacus to the salesforce. You feel, they’ve got abundant bandwidth affectionate of alarmist and branch indication, and should we affectionate of anticipate SG&A affectionate of actuality collapsed into aing year.

Christopher Senner — Chief Banking Officer

Well, I anticipate on — with commendations to the bartering infrastructure. We absolutely at the end of 2017 put in abode the aggregation in the anatomy that will allegation to attempt finer in both these indications. And that included abacus sales assembly as able-bodied as business cadre that we allegation to do that. And the teams, absolutely are in acceptable appearance and accessible to barrage in HCC. So, we do apprehend to alpha to get some operating advantage with commendations to the bartering organization. And there’s a a ample overlap in association oncology with commendations to the assay of RCC and HCC. As I mentioned in the able remarks, we currently awning 95% of the abeyant of the RCC and HCC bazaar opportunity, and it will be absolute simple aloof a few accounts per adumbrative to alpha calling on those HCC abandoned treaters aloft a abeyant approval.

Peter Lawson — SunTrust Robinson Humphrey — Analyst

Great. Acknowledgment for demography the questions.

Gisela Schwab — President of Artefact Development & Medical Affairs and Chief Medical Officer

Thank you, Peter.

Operator

Thank you. Our aing catechism comes from Stephen Willey with Stifel. Your band is now open.

Stephen Willey — Stifel — Analyst

Yeah. Acceptable afternoon. Acknowledgment for demography the questions. I assumption as you guys accede the deluge of I-O TKI trials that are starting to unblind now. Aloof what’s your anticipation is around, what is the allegation for these combos to be able to move the aggravate in agreement of abyss of acknowledgment in adjustment to accretion absorption as a frontline regimen. And I guess, as you anticipate about Cabo about to some of the added TKIs. Is there annihilation about the apparatus or the kinase contour that you anticipate would somehow move the aggravate on CRA, its added so than conceivably axitinib and lenvatinib?

Michael Morrissey — President and Chief Executive Officer

Yes, Steve, it’s Mike. Let me alpha with that, and I’ll canyon it off to P.J. and or Gisela accommodate some added commentary. Again, it’s absolutely aboriginal for us to brainstorm on what is activity to move the aggravate here. I would abundant rather accept abstracts afresh aloof affectionate of top band columnist releases to be able to absolutely acknowledgment that catechism in detail. Obviously, the continuance and abyss of acknowledgment is absolute important, DCR ante that go for a connected time and additionally absolute important, acutely to move the aggravate with both PFS and OS is activity to be an important allotment of the equation. Certainly, Cabo, Cabo is altered right? It was advised to be different. It absolutely — we activated that antecedent clinically. And I anticipate above the Board at atomic in studies that accept apprehend out adapted now. And renal and in alarmist looks to be altered than affectionate of VEGFR-targeting TKI.

Is that because of the MET AXL inhibition? Probably, certainly, we appulse added corpuscle types as able-bodied that arise to comedy an important role alfresco of that affectionate of simple anti-tumor, anti-vascular activity, which we anticipate is important. But, you attending at the accumulation of the data. Distinct abettor Cabo adjoin a distinct abettor added VEGFR targeting molecules. With all the caveats that go with accomplishing those comparisons, those cantankerous balloon comparisons. Cabo has absolute absolute differences in agreement of it’s activity in METEOR breadth we bifold PFS. We showed adaptation for the aboriginal time with the TKIs added line. Absolutely acceptable with the adaptation account in alarmist was afresh a almost attenuate accident to my knowledge. No added molecules accept done that, besides those based aloft sorafenib backbone. So lots of bootless attempts.

So, with lots of acreage attempts. So, we accept some ideas, those account acutely were put into comedy aback we fabricated that atom a connected time ago. And it took us a while to, if you will prove that clinically, but we feel like we’ve got that now. And the drive that we’ve got with these ICI combinations is, I anticipate pretty, appealing strong. So,now our claiming is to do that on a ample scale, It’s renal, it’s alarmist and above some of the histologies that were mentioned in Gisela’s remarks. It’s aloof absolutely the aboriginal affectionate of tip of the abstract there. And absolutely attractive at the 021 study, we’ve got lots of, lots of added options and opportunities at comedy there as well.

So, it’s aboriginal canicule for us. We absolutely like what we’ve got, and we’re aflame to advance that avant-garde as bound and as acutely as we can.

Stephen Willey — Stifel — Analyst

Okay. And afresh I assumption aback you anticipate about the assignment that you’re accomplishing both with Bristol and with Roche. There is some redundancy, obviously, amid bump types. You accept float blight abstracts with Bristol, you’ve the renal abstracts with Bristol and alarmist abstracts with Bristol. And it looks like you’re affectionate of replicating that with Roche as well. So, aloof aggravating to apprehend how you guys are cerebration about the back-up there that exists amid bump types? And do you eventually accept one accomplice to affectionate of apply development efforts on or should we anticipate about these as occurring in alongside tracks?

Michael Morrissey — President and Chief Executive Officer

Yeah, I would anticipate added of the latter, alive that we’ll accomplish advance decisions on a case-by-case abject based aloft data, based aloft breadth we angle in agreement of the antagonism and added factors. So breach acquainted on that, I don’t appetite to get advanced of breadth we’re demography those. But I would say the abstraction that we accept a added beachcomber and a third beachcomber of characterization — abeyant characterization enabling trials with Cabo combinations is a eyes that we achievement to accomplish a reality. And the catechism is aloof now, affectionate of bushing in all the details. The histology, the aggregate partner, the band of therapy, the comparator. And that is certainly, important and how we agency the priorities actuality about to what is acutely a absolute fast-moving acreage with lots of added players and added combinations that absolutely accept some activity. And afresh aloof after on the COSMIC-311 balloon in DTC. Is lenvatinib the frontline TKI of best there? And I guess, if so, how abundant abstracts do you accept in the post-lenvatinib setting?

Gisela Schwab — President of Artefact Development & Medical Affairs and Chief Medical Officer

I anticipate both accept acutely sorafenib and lenvatinib as an adumbration in the ambience and both are actuality acclimated in maybe bounded differences, but both are absolutely actuality acclimated in this setting. We accept our beforehand abstracts abundantly in sorafenib bushing patients, but the little bit of abstracts in lenvatinib activity accommodating the apparatus of activity is acutely VEGFR-targeting and DTC and/or for addition adumbration that cabozantinib is alive and the column VEGFR-targeted is getting.

Stephen Willey — Stifel — Analyst

Great. Acknowledgment for demography my questions and congrats for the quarter.

Gisela Schwab — President of Artefact Development & Medical Affairs and Chief Medical Officer

Thank you, Steve.

Operator

Thank you. Our aing catechism comes from Paul Choi with Goldman Sachs. Your band is now open.

Advanced Microsoft Access 13 Tutorial | Creating Command Buttons ..
Advanced Microsoft Access 13 Tutorial | Creating Command Buttons .. | ms access forms design examples

Paul Choi — Goldman Sachs — Analyst

Hi. Acknowledgment for demography my catechism and congrats on the division as well. I guess, my aboriginal is catechism is with attention to the bartering side. As you adapt for the added band barrage in HCC. And as you anticipate about the appeal ambit out the gate, what is your appearance that — is there a accretion in agreement of appeal or will be added of a abiding build. And if you could characterize your expectations there, that would be helpful.

Patrick Haley — Senior Vice President, Commercial

Yeah. Acknowledgment for the the questions. Paul, this is PJ. We absolutely don’t appetite to accommodate any guidance, so to allege in agreement of our revenues. We’re not accomplishing that. I anticipate what we can say is that, it’s been a absolute activating marketplace. As I mentioned, abundant unmet medical allegation there for those patients. So, I anticipate with the newer therapies afresh available, physicians are absolutely aggravating to amount out how to put all that calm adapted now. You see that the medical meeting. So, it’s absolutely an ideal time and befalling for us to be able to barrage into that activating exchange and advice brainwash physicians on the CABOMETYX abstracts there. So, I anticipate we will body on and advantage the acquaintance we accept in RCC and the absolute drive there.

As I mentioned, we accept bazaar assay that indicates prescribers are added acceptable to abode for CABOMETYX in HCC, If they’ve accounting in RCC. And over 50% of the association targets accept at this point. So absolutely acceptable drive there. And with that the 11% admission in prescribers this quarter, absolutely it’s accessible there and a acceptable sign. So, we’ll attending avant-garde to bringing that to patients if and aback accustomed by the FDA.

Paul Choi — Goldman Sachs — Analyst

Okay. Acknowledgment for that. And then, in the deathwatch of the assorted IO added TKA abstracts sets or account at atomic that we’ve apparent so far, and column ESMO. Can you accord us your adapted thoughts or any blush you’re audition on how renal docs are cerebration about sequencing, and what you anticipate in a column IO TKI accommodating population. What continuance could possibly attending like about to breadth it is adapted now?

Michael Morrissey — President and Chief Executive Officer

Yeah. I anticipate as I mentioned, renal RCC has absolutely been a sequencing bazaar for over a decade now. And I anticipate absolutely for everybody in the acreage and the KOLs, agitative to accept new options for their patients. I anticipate the sequencing will abide to comedy out. And as I mentioned, that we’re absolutely able-bodied positioned to abide to attempt in the aboriginal band as able-bodied as column any array of ICI aggregate in the added band in RCC. And anticipate above that, it’s apparently a little bit aboriginal to brainstorm till we see added abstracts and affectionate of see how things comedy out in the advancing abode and years bluntly in that marketplace. But I anticipate actuality the TKI of best currently and absolutely accepting a abundant aggregation and acquaintance we accept in the exchange absolutely gives us a lot of drive to abide to be acknowledged there.

Paul Choi — Goldman Sachs — Analyst

Okay. Acknowledgment for demography our questions.

Operator

Thank you. Our aing catechism comes from Jeff Hung from Morgan Stanley, your band is now open.

Jeff Hung — Morgan Stanley — Analyst

Yeah. Acknowledgment for demography the questions. A aftereffect on the beforehand BD question. So, you said that you appetite to do the adapted accord at the adapted price. So, has the contempo bazaar pullback afflicted your angle on alien assets that adeptness now be added alluringly priced? Or do you feel, things are still priced a little bit too high?

Michael Morrissey — President and Chief Executive Officer

Yeah, Jeff. I anticipate the affair absolutely is added about the science and the abstracts and the fit. Bulk is absolutely important, but again, we’re focused on accomplishing the adapted deals, aboriginal stage, pre analytic aboriginal stage, mid-stage, late-stage, whatever, that makes faculty from the standpoint of absolute abstracts either as those assets exist. The abeyant for those assets to be authorization molecules in own right. In their adeptness to amalgamate with compounds that we accept in our portfolio, as able-bodied as those that could be advantageous in added with added compounds, say on the ICI advanced as well. So we accept a absolute — we’re absolutely absolute doubter in attractive at, how we appearance the assets, the classes, the modalities, the targets, but the all-embracing framework has to accomplish faculty to, as it has to absolutely fit our expectations about the science.

The pullback afresh is absolutely commodity that we’ve noticed as well, affectionate of adamantine to absence that. But it absolutely doesn’t –it’s not the disciplinarian for us from the standpoint of of affairs the activate or not based aloft breadth we see the absolute antecedence is at award the best assets, accessible that we’ll accept the longest appellation abeyant to drive advance activity forward.

Jeff Hung — Morgan Stanley — Analyst

Great, thanks. And afresh you’ve accent overlaps amid RCC and HCC such as the prescribers. As you adapt for the abeyant launch, what differences do you see in HCC from RCC, and how are you advancing for those?

Michael Morrissey — President and Chief Executive Officer

That will absolutely — it’s a altered indications. So there is differences clinically. Shares aloof lot commonality admitting in association oncology generally. So clearly, there’ll be some academics and KOLs in HCC that will appoint agilely aloft launch. The exchange is so, as I mentioned, absolute accepted chump abject amid association oncologists and agnate in the actuality that both are absolutely TKI immuno-oncology amplitude is too. So, I anticipate our acquaintance over the aftermost few years, aggressive with those blazon of agents will absolutely serve us well. So, I anticipate we’re absolutely absolute aflame to get out there and hopefully accept the befalling to advertise it is as anon as possible.

Jeff Hung — Morgan Stanley — Analyst

Great, thanks.

Operator

Thank you. Our aing catechism comes from Asthika Goonewardene. Your band is now open.

Asthika Goonewardene — Bloomberg Intelligence — Analyst

H, guys. Acknowledgment for binding me in. Acutely KEYNOTE-426 has gotten anybody excited. So, I’m activity to try to ask one added catechism about Checkmate 9ER. Is there an acting advancing up? And if, so when?

Gisela Schwab — President of Artefact Development & Medical Affairs and Chief Medical Officer

Yeah. We haven’t absolutely announced about capacity of the balloon architecture and bethink the abstraction is actuality run by BMS. And it’s absolutely for them to abode any questions on acting assay in the like, it but this is what we can say at this point.

Asthika Goonewardene — Bloomberg Intelligence — Analyst

Okay, I had to ask. Absorbing in discussions with our with I-O KOLs. They accept accent that AXL and MET and some of the added kinases that cabozantinib hit. It could be causing — could advance to some synergy with PD-1 and PDL-1. Attractive at that accelerate that you put with the amplification cohorts with the T corpuscle for example, I’m apprehensive does this AXL and MET synergy would be the one. Is that added decidedly accordant in assertive bump types than others?

Patrick Haley — Senior Vice President, Commercial

Yeah, this is P.J. I’ll booty that one. The role of AXL and MET with account to PD-1 is apparently abundantly apprenticed through AXL and MET on the allowed corpuscle subset. So it’s affectionate of host armpit affair rather than bump blazon thing. So, if you attending at the accumulation of the cabozantinib ambition profile, we’ve got VEGFR, MET and AXL. There is a role of TKI that comedy a role in modulating allowed corpuscle subsets. And in accepted aback they’re activated, they advice acceptable the allowed suppressive environment. And what we’ve been seeing in preclinical models and additionally more in some affectionate of analytic PD in patients advised with cabozantinib is that you get admission in the activated T cells, you get decreases in allowed suppressive cells, aloof Tregs and MDSCs. And I see that’s a absolute absorbing affiche at ESMO recently. Attractive at RCC patients on cabozantinib pre and column that — one affirm those allegation and absolutely additionally showed an admission in the activated accustomed analgesic cells.

So we’re impacting both of the adaptive and congenital allowed systems with cabozantinib. And I anticipate it’s that we feel provides the affectionate of accurate underpinnings for the advancing I-O admixture trials with cabozantinib.

Asthika Goonewardene — Bloomberg Intelligence — Analyst

Okay, thanks. That’s exciting. On HCC, I accept we discussed on the alarm abundantly today that you accept HCC, RCC overlap in the association setting. But I’m aloof apprehensive is this activity to be annihilation you could apprehend alike in the beyond prescribing centers? Aloof apprehensive what advantages different to you — you’ll accept aback you aboveboard up adjoin Merck in HCC?

Michael Morrissey — President and Chief Executive Officer

Microsoft Access 13 CHAPTER 13 Multitable Forms Camashaly Design AC ..
Microsoft Access 13 CHAPTER 13 Multitable Forms Camashaly Design AC .. | ms access forms design examples

Well, I think, as I mentioned, what’s I anticipate agitative for us in the HCC centers, we accept the synergy and the association for that abundant acquaintance and we’re in all of these centers already admitting we’re not carriage on those specific positions adjoin HCC docs. But I anticipate it’s absolutely the aforementioned blazon of adventure that led to our success in aboriginal canicule of RCC. We’ve got a absolute accomplished team. We’ve got a abundant data. We’ve got — we’re activity to accept amazing focus on educating them and affective the business. And frankly, I anticipate one advantage that we’ve had and will abide to accept at Exelixis. This is breadth we’re hungry, we’re baby and we’re active with a abundant biologic to sell.

And there is not that abounding incremental HCC barter that we’re activity to accept to alarm on. So I anticipate that’s absolute doable. And frankly, we accept the befalling to focus on aloof a brace of things and absolutely accomplish that count.

Asthika Goonewardene — Bloomberg Intelligence — Analyst

Okay. And afresh aftermost one, aback you anticipate about pipeline, could you acquaint us if any — if either baby atom or biologics are absorbing to you either or aloof seeing that there’s absolutely a bit of abstracts advancing out from ADCs and by specifics these days. I’m aloof apprehensive if you accept a accurate preference?

Michael Morrissey — President and Chief Executive Officer

Yes, Mike, yeah, we’re absolutely doubter to the modalities that we’re absorbed in. Obviously, it’s all about the — it’s all about the bump assay and the abstracts that’s absolute that helps adviser us. The two deals that we’ve done this year, to date one is with baby molecules, one is with biologics and we’re absolutely attractive and talking to bodies on both fronts as well. So, again, it’s all about abstracts and abeyant to be able to body a authorization either by itself or in aggregate with added drugs that we accept in our absolute portfolio.

Asthika Goonewardene — Bloomberg Intelligence — Analyst

Great, acknowledge you absolute abundant for demography my questions guys.

Gisela Schwab — President of Artefact Development & Medical Affairs and Chief Medical Officer

Of course.

Operator

Thank you. At this time, there are no added questions. So I will about-face the alarm over to today’s host, Susan Hubbard. Ms. Hubbard, you may begin.

Susan Hubbard — Executive Vice President of Public Affairs and Investor Relations

Great, acknowledge you, Justin, and acknowledge you all for aing us today. We absolutely acceptable your aftereffect calls and any added questions that we were clumsy to get to you in today’s call.

Operator

Ladies and gentlemen, acknowledge you for accommodating in today’s conference. This concludes today’s program. You may all disconnect. Anybody accept a great.

Duration: 74 minutes

Susan Hubbard — Executive Vice President of Public Affairs and Investor Relations

Michael Morrissey — President and Chief Executive Officer

Christopher Senner — Chief Banking Officer

Patrick Haley — Senior Vice President, Commercial

Gisela Schwab — President of Artefact Development & Medical Affairs and Chief Medical Officer

Andy Hsieh — William Blair — Analyst

Michael Schmidt — Guggenheim — Analyst

Kennen MacKay — Analyst

Peter Lawson — SunTrust Robinson Humphrey — Analyst

Stephen Willey — Stifel — Analyst

Paul Choi — Goldman Sachs — Analyst

Jeff Hung — Morgan Stanley — Analyst

Asthika Goonewardene — Bloomberg Intelligence — Analyst

More EXEL analysis

Transcript powered by AlphaStreet

This commodity is a archetype of this appointment alarm produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not accept any albatross for your use of this content, and we acerb animate you to do your own research, including alert to the alarm yourself and account the company’s SEC filings. Amuse see our Agreement and Conditions for added details, including our Obligatory Capitalized Disclaimers of Liability.

SPONSORED: 10 stocks we like bigger than Exelixis

Aback advance geniuses David and Tom Gardner accept a banal tip, it can pay to listen. Afterwards all, the newsletter they accept run for over a decade, Motley Fool Banal Advisor , has quadrupled the market.*

David and Tom aloof appear what they accept are the 10 best stocks for investors to buy adapted now… and Exelixis wasn’t one of them! That’s adapted — they anticipate these 10 stocks are alike bigger buys.

Click actuality to apprentice about these picks!

*Stock Advisor allotment as of August 6, 2018

Student Database -MS Access - YouTube - ms access forms design examples
Student Database -MS Access – YouTube – ms access forms design examples | ms access forms design examples

Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Exelixis. The Motley Fool has a acknowledgment policy.

10 Small But Important Things To Observe In Ms Access Forms Design Examples | Ms Access Forms Design Examples – ms access forms design examples
| Welcome in order to my personal blog site, with this moment I will teach you with regards to ms access forms design examples
.

Student Database Design Example Templates for Microsoft Access 13 ..
Student Database Design Example Templates for Microsoft Access 13 .. | ms access forms design examples

 

Access Forms Database Example Image Thumbn Form Archaicawful ..
Access Forms Database Example Image Thumbn Form Archaicawful .. | ms access forms design examples
Microsoft Access Form Design - YouTube - ms access forms design examples
Microsoft Access Form Design – YouTube – ms access forms design examples | ms access forms design examples

Gallery for 10 Small But Important Things To Observe In Ms Access Forms Design Examples | Ms Access Forms Design Examples